Target- |
MechanismCell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.
100 Clinical Results associated with Wuhan Yishou Technology Co., Ltd.
0 Patents (Medical) associated with Wuhan Yishou Technology Co., Ltd.
100 Deals associated with Wuhan Yishou Technology Co., Ltd.
100 Translational Medicine associated with Wuhan Yishou Technology Co., Ltd.